GENECLUST
GENECLUST is a tool for exploratory analysis of gene expression microarray data.
Multiple Outcomes
multcomp99 Version 2.0, February 2000
multcomp99 is a program for the design of clinical trials with
multiple outcomes. This program was written by Hsi-Guang Sung
under the supervision of Peter Thall.
Files:
UNIX
Windows: not yet available
References:
Thall PF, Simon R, Estey EH. Bayesian sequential monitoring
designs for single-arm clinical trials with multiple outcomes.
Statistics in Medicine 1995;14:357-379.
Thall PF, Simon R, Estey EH. New statistical strategy for monitoring
safety and efficacy in single-arm clinical trials. Journal of
Clinical Oncology 1996;14:296-303.
Thall PF, Sung H-G. Some extensions and applications of a Bayesian
strategy for monitoring multiple outcomes in clinical trials.
Statistics in Medicine 1998;17:1563-1580.
Continual Reassessment Method (CRM)
For Dose-finding In Phase I Clinical Trials
CRM Version 1.0, February 1999
CRM is a menu-driven computer program that implements the Continual
Reassessment Method (CRM) for dose-finding in phase I clinical
trials. Designed for use by physicians, research nurses and
statisticians, CRM provides a means to log in patients as they are
accrued to a trial, to record their outcomes from treatment (toxicity
or no toxicity), and to select doses for successive cohorts of
patients based on the current data. Dose selection is performed
using the Bayesian method underlying the CRM.
The CRM was originally proposed by O'Quigley, Pepe and Fisher
(Biometrics 1990;46:33-48). John Venier wrote this program under
the supervision of Peter Thall. Documentation accompanying the
package also contains a fairly complete bibliography.
Files:
UNIX:
Source in Fortran 90 and Fortran 77 plus documentation
Windows:
Self-extracting file of Win32 PC executable plus documentation
Mac OS:
Self-extracting file of Power Macintosh executable plus documentation
References:
O'Quigley J, Pepe M, Fisher L. Continual reassessment method:
a practical design for phase I clinical trials in cancer. Biometrics 1990;46:33-48.
Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I
trials with delayed patient outcome. Statistics in Medicine 1999;18:1155-1169.
Efficacy and Toxicity Dose-outcome Model
efftox99 Version 3, January 1999
efftox99 is a program to simulate designs constructed using the
dose-finding strategy proposed by Thall and Russell under a
three-category efficacy/toxicity dose-outcome model. This program
was written by Kathy Russell and modified by Hsi-Guang Sung under
the supervision of Peter Thall.
Files:
UNIX
Windows
References:
Thall PF, Russell KE. A strategy for dose-finding and safety
monitoring based on efficacy and adverse outcomes in phase I/II
clinical trials. Biometrics 1998;54:25111-264.
Thall PF, Estey EH, Sung HG. A new statistical method for
dose-finding based on efficacy and toxicity in early phase clinical
trials. Investigational New Drugs 1999;17:155-167.
